NGM Biopharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

NGM Biopharmaceuticals

05/08/2021 23:39

* NGM Biopharmaceuticals Inc  NGM.OQ  reported a quarterly
adjusted loss of 48 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 37 cents per share.
* Revenue fell 15.1% to $16.77 million from a year ago; 
analysts expected $22.48 million. 
* NGM Biopharmaceuticals Inc's reported EPS for the quarter was
a loss of 48 cents​.
* The mean earnings estimate of analysts had risen by about 15%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* NGM Biopharmaceuticals Inc shares had risen by 12.2% this
quarter and lost 27.0% so far this year.
* The company reported a quarterly loss of $36.69 million.
* Wall Street's median 12-month price target for NGM
Biopharmaceuticals Inc is $21.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 5 at 10:39 p.m.  ​All
figures in US dollars unless otherwise stated